10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
21.65
-0.78 (-3.48%)
At close: May 4, 2026, 4:00 PM EDT
21.65
0.00 (0.00%)
Pre-market: May 5, 2026, 4:00 AM EDT
← View all transcripts

AGM 2023

Jun 14, 2023

Operator

Hello, and welcome to the 2023 10x Genomics Annual Meeting of Stockholders. Please note that this meeting is being recorded. Questions may be submitted via the message icon at the top left of your screen, typing your message, then clicking the send icon to the right of the message box. It is now my pleasure to turn the meeting over to Dr. Serge Saxonov, Co-founder and Chief Executive Officer of 10x Genomics. Dr. Saxonov, the floor is yours.

Serge Saxonov
Co-founder and CEO, 10x Genomics

Good afternoon. It is a pleasure to welcome all of you to the 2023 Annual Meeting of Stockholders of 10x Genomics, Inc. Call this meeting to order. I'm Serge Saxonov, Co-founder, Chief Executive Officer, and a member of the Board of Directors of 10x Genomics, and I will act as chairperson of the meeting. Eric Whitaker, our Chief Legal Officer, joins me in welcoming you today. I would also like to welcome the members of our board of directors and our executive team who are present at today's meeting. Vandana Sidu, 10x's Corporate and Securities Counsel, will act as secretary of the meeting. I'm also pleased to welcome Dan Coleman and Matt Kahn, representatives of Ernst & Young, our external auditing firm, who are here to answer any appropriate questions. In addition, I'd like to welcome John Lundberg, a representative of American Stock Transfer & Trust Company, LLC, our transfer agent, who has been appointed to act as our inspector of election. Mr. Lundberg has signed an oath of office, which will be filed with the minutes of this meeting. Please note that this meeting is being recorded, and a replay of the audio cast will be posted to the investor relations section of our website at https://investors.10xgenomics.com as soon as practical.

Good afternoon. I'm Eric Whitaker, Chief Legal Officer of 10x Genomics. This meeting is the company's fourth annual meeting of stockholders as a public company. It's also our fourth annual meeting conducted via live webcast. We believe in engaging our stockholders and maximizing their ability to meaningfully engage with us. Today's virtual annual meeting allows our stockholders to participate in the meeting, regardless of their location. Stockholders are also permitted to submit questions and vote their shares online before the polls close. I will now turn the meeting over to Vandana, who will explain certain procedures for today's meeting.

Vandana Sidhu
Corporate and Securities Counsel, 10x Genomics

Thanks, Eric. Before we get started, I would like to cover a few administrative matters. Today's meeting has been duly called and is being conducted in conformity with the laws of the State of Delaware and the company's charter and bylaws. The rules of conduct and procedures for this meeting are available by clicking the Documents icon at the top of the left side of your screen, then click on the document titled Rules of Conduct and Procedures to view. It is 1:33 P.M. The polls are open for voting and will close after a brief discussion of the proposals scheduled to be voted on today. If you have already voted and do not wish to change your vote, you do not need to do anything.

If you haven't voted or if you voted previously but want to change your vote, you may do so now online by clicking on the proxy voting site link on the left side of your screen. We have three proposals scheduled to be voted on today. Serge will introduce each of the three proposals. We will then pause for questions on the proposals before closing the polls. The polls for each matter upon which stockholders will vote at this meeting will remain open until we announce that the polls are closed. No ballots or proxies or revocations or changes of proxy will be accepted after the polls are closed.

Under Section 2.03 of the company's bylaws, in order for a stockholder proposal to have been properly brought before this 2023 annual meeting of stockholders, the proposal was required to be submitted to the company's secretary not later than the close of business on the 90th day and not earlier than the close of business on the 120th day prior to June 14, 2023. No such proposals were submitted with respect to this annual meeting, no such proposals will be considered at this meeting. We will provide the preliminary results of the voting based on a preliminary report from Mr. Lundberg, who, as mentioned by Serge, has been appointed to act as Inspector of Election and is present at the meeting today.

To submit any questions, you may do so by clicking on the Messages icon at the top of the left side of your screen. Type your question into the text box, then click the send icon at the right side of that text box. In order to ensure that the business of the meeting proceeds in an orderly fashion, we ask that you please observe the meeting rules and only submit questions directly related to the business of the meeting. Also out of consideration for others, please limit yourself to 2 questions at a time. Please note that only validated stockholders with a control number will be able to ask questions, and in the interest of all stockholders, we will only address those questions that are pertinent to the business of the meeting. We will then adjourn the meeting.

It is possible our discussion at today's meeting, including some of our comments and responses to your questions, may include forward-looking statements, which are predictions, projections, or other statements about future events. These statements are not historical facts and are subject to known and unknown risks, uncertainties, and other factors, which may cause our actual results, performance, or achievements to be materially different from such anticipated results, performance, or achievements expressed or implied by such forward-looking statements. Accordingly, such forward-looking statements should not be relied upon. Except to the extent required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements. Thus, it should not be assumed that our silence over time means that actual events are occurring as expressed or implied in such forward-looking statements.

Please refer to our discussion set forth under the Forward-Looking Statements section of our earnings releases, as well as under the caption Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our quarterly report on Form 10-Q for the first quarter ended March 31, 2023. As such risks, uncertainties, and factors may be updated in the company's periodic filings with the SEC. With that, I will now turn it back over to Serge.

Serge Saxonov
Co-founder and CEO, 10x Genomics

Thanks, Vandana. AST has delivered an affidavit of mailing that shows that proper advance notice of this meeting and distribution of these documents was given to our stockholders of record as of the close of business on April 19, 2023, the date fixed by our board of directors as the record date for the determination of stockholders entitled to receive notice of and to vote at this meeting. A copy of the notice of this meeting and the affidavit of mailing will be incorporated into the meeting minutes of this meeting. All stockholders of record at the close of business on April 19, 2023, are entitled to vote at this annual meeting, a list of stockholders of record is available for your review by clicking on the Documents icon at the top of the left side of your screen.

Click on the document titled List of Stockholders to view. Our first item of business is to determine whether we have a quorum for the purpose of transacting business. Mr. Lundberg, do you have a report?

John Lundberg
Representative, American Stock Transfer and Trust Company, LLC

Yes. The stockholders' list shows that holders of 98,117,778 shares of Class A common stock and 18,067,255 shares of Class B common stock of the company, for a combined total of 278,790,328 votes, are entitled to vote at this meeting. There are represented in person or by proxy at this meeting, a combined total of 238,312,359 votes, representing approximately 85.48% of the voting power of the Class A and Class B shares entitled to vote at this meeting.

Serge Saxonov
Co-founder and CEO, 10x Genomics

Thank you. Because holders of a majority of the voting power of the shares entitled to vote at this meeting are present in person or by proxy, we have a quorum for the transaction of business, this meeting is duly convened. The next item of business is a description of the matters to be voted on at today's meeting. After all of the proposals have been presented, we will answer questions submitted by the stockholders. The polls will close after this discussion. The first proposal is the election of three Class I director nominees, each to serve a three-year term expiring at our 2026 Annual Meeting of Stockholders, or until such director's successor is duly elected and qualified, or until such director's earlier death, resignation, disqualification, or removal.

The board of directors recommends the election of Serge Saxonov, Ben Hindson, and John Stuelpnagel as Class I directors of the company. Because we have an advance notice provision in our bylaws, all further nominations are closed. The next proposal is the ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for our fiscal year ending December 31st, 2023. The board of directors recommends that stockholders vote in favor of this proposal. Finally, the last proposal is to consider a non-binding advisory resolution, commonly known as a say-on-pay proposal, to approve the compensation of our named executive officers. The board of directors recommends that stockholders vote in favor of this proposal. This concludes our presentation of the proposals at this meeting. Does anyone have any questions related to any of the proposals?

Vandana Sidhu
Corporate and Securities Counsel, 10x Genomics

Thanks, Serge and Eric. At this time, no questions have been submitted by stockholders. Having not received any questions, I'm now going to proceed with the voting. As noted previously, if you have already voted and do not wish to change your vote, you do not need to do anything. If you haven't voted or if you voted previously but want to change your vote, you may now do so online by clicking on the proxy voting site link on the left side of your screen. The polls will be closing shortly. Now that time has been given to vote, it is 1:42 P.M. I hereby declare the polls closed for voting.

Serge Saxonov
Co-founder and CEO, 10x Genomics

At this time, I will ask Vandana to report the preliminary results of the voting.

Vandana Sidhu
Corporate and Securities Counsel, 10x Genomics

The preliminary report of the Inspector of Election indicates that each of Serge Saxonov, Ben Hindson, and John Stuelpnagel has been duly elected to our board of directors, that the appointment of Ernst & Young as independent registered public accounting firm for fiscal year 2023 has been ratified, and that our stockholders have approved on a non-binding advisory basis, the compensation paid to our named executive officers. The final voting results will be contained in a Form 8-K that will be filed with the SEC within four business days following this meeting. This concludes the formal business of the meeting.

Serge Saxonov
Co-founder and CEO, 10x Genomics

Thank you for attending today's meeting. We will now entertain questions from stockholders. Representatives from EY are also available to answer appropriate questions from stockholders. Please be mindful of the voting rules.

Powered by